Research programme: P2X7 receptor antagonists - AstraZeneca
Latest Information Update: 16 Jul 2016
At a glance
- Originator AstraZeneca
- Class Small molecules
- Mechanism of Action Purinergic P2X7 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bone disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-disorders in United Kingdom